EMEnrique Miranda-Peralta

Enrique Miranda-Peralta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Enrique Miranda-Peralta has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical significance of the ABCB1 and ABCG2 gene expression levels in acute lymphoblastic leukemia

    by I. Olarte Carrillo, C. Ramos Peñafiel, E. Miranda Peralta, E. Rozen Fuller, J. J. Kassack Ipiña, F. Centeno Cruz, E. Garrido Guerrero, J. Collazo Jaloma, K. Nacho Vargas, A. Martínez Tovar

    Objectives: Acute lymphoblastic leukemia (ALL) is a clonal disease that accounts for 20% of acute leukemias in adults. A high percentage of adult patients (ranging from 70 to 80%) reach complete remission; however, the 5-year survival rate is only 20–40%. One of the main obstacles to treatment success is the drug resistance of leukemic cells. Therefore, our research group analyzed the ABCB1 and ABCG2 gene expression levels in 61 patients diagnosed with ALL and assessed whether the levels affected the clinical parameters and 40-month survival rate. Methods: The ABCB1 and ABCG2 gene expression levels were analyzed using real-time polymerase chain reaction in 61 patients diagnosed with ALL and 99 healthy donors as controls. The association between ABCB1 and ABCG2 gene expression levels and clinical variables was determined using the Chi-square test and Fisher’s exact test. Overall survival (OS) was determined using the Kaplan–Meier method. Results: The results showed high ABCB1 and ABCG2 gene levels, which were 4.5 and 2.3 times the levels of healthy donors, respectively. A total of 52% of the study patients expressed high ABCB1 levels and were significantly associated with the high-risk patient group and a decreased 40-month survival rate of 78%. Only 49% of the patients expressed high ABCG2 gene levels. No association was found between the clinical parameters and the ABCG2 gene expression levels. Conclusions: Early detection of ABCB1 gene expression levels could be important for the diagnosis and monitoring of ALL patients.


  • Open Access

    Frequency of the minor BCR-ABL (e1;a2) transcript oncogene in a Mexican population with adult acute lymphoblastic leukaemia

    by I. Olarte-Carrillo, C.O. Ramos-Peñafiel, E. Miranda-Peralta, I. Mendoza-Salas, K.A. Nacho-Vargas, J.A. Zamora-Domínguez, E. Mendoza-García, E. Rozen-Fuller, J.J. Kassack-Ipiña, J. Collazo-Jaloma, et al.


  • Open Access

    Prevalence of Gene Rearrangements in Mexican Children with Acute Lymphoblastic Leukemia: A Population Study—Report from the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia

    by Vilma Carolina Bekker-Méndez, Enrique Miranda-Peralta, Juan Carlos Núñez-Enríquez, Irma Olarte-Carrillo, Francisco Xavier Guerra-Castillo, Ericka Nelly Pompa-Mera, Alicia Ocaña-Mondragón, Angélica Rangel-López, Roberto Bernáldez-Ríos, Aurora Medina-Sanson, et al.

    Mexico has one of the highest incidences of childhood leukemia worldwide and significantly higher mortality rates for this disease compared with other countries. One possible cause is the high prevalence of gene rearrangements associated with the etiology or with a poor prognosis of childhood acute lymphoblastic leukemia (ALL). The aims of this multicenter study were to determine the prevalence of the four most common gene rearrangements [ETV6-RUNX1, TCF3-PBX1, BCR-ABL1, andMLLrearrangements] and to explore their relationship with mortality rates during the first year of treatment in ALL children from Mexico City. Patients were recruited from eight public hospitals during 2010–2012. A total of 282 bone marrow samples were obtained at each child’s diagnosis for screening by conventional and multiplex reverse transcription polymerase chain reaction to determine the gene rearrangements. Gene rearrangements were detected in 50 (17.7%) patients.ETV6-RUNX1was detected in 21 (7.4%) patients,TCF3-PBX1in 20 (7.1%) patients,BCR-ABL1in 5 (1.8%) patients, andMLLrearrangements in 4 (1.4%) patients. The earliest deaths occurred at months 1, 2, and 3 after diagnosis in patients withMLL, ETV6-RUNX1, andBCR-ABL1gene rearrangements, respectively. Gene rearrangements could be related to the aggressiveness of leukemia observed in Mexican children.


  • Open Access

    Casein induces the proliferation of bone marrow mononuclear cells, apoptosis of WEHI-3 leukaemic cells and increased survival in a leukaemia mouse model

    by E. Ledesma-Martínez, C. Pérez-Cordero, Y. Córdova-Galaviz, G. Sánchez-Tellez, S. Huerta-Yepez, I. Aguiñiga-Sánchez, E. Miranda-Peralta, A. Monroy-García, B. Weiss-Steider, E. Santiago-Osorio

    Acute myeloid leukaemia results from the neoplastic transformation of haematopoietic stem cells. Although advances have been made in its treatment, the mortality rate remains high. As a result, therapeutic alternatives continue to be explored. In this study, we present evidence that suggests that casein, the principal protein in milk, possesses significant antileukaemic properties. We investigated whether casein inhibited the in vitro proliferation and induced the apoptosis of the mouse myelomonocytic leukaemia cell line WEHI-3. By contrast, under identical conditions, casein markedly promotes the proliferation of mouse normal mononuclear bone marrow cells. Since the selective elimination of leukaemia cells is an ideal therapeutic strategy, we also evaluated the antileukaemic potential of casein in vivo. The results showed that casein increases the survival of mice bearing WEHI-3-induced tumours, suggesting that this molecule is also capable of inhibiting the proliferation of these cells in vivo. The evidence that casein inhibited cell proliferation and induced apoptosis in leukaemia cells in vitro, but increased survival in vivo in a leukaemia mouse model, indicates that casein may be useful in leukaemia therapy.


  • BCR-ABL, ETV6-RUNX1 and E2A-PBX1: Prevalence of the most common acute lymphoblastic leukemia fusion genes in Mexican patients

    by S. Jiménez-Morales, E. Miranda-Peralta, Y. Saldaña-Alvarez, P. Perez-Vera, R. Paredes-Aguilera, R. Rivera-Luna, R. Velázquez-Cruz, J. Ramírez-Bello, A. Carnevale, L. Orozco


  • Deficient proliferation and expansionin vitroof two bone marrow cell populations from patients with acute myeloid leukemia in response to hematopoietic cytokines

    by Juan José Montesinos, Elizabeth Sánchez-Valle, Eugenia Flores-Figueroa, Guadalupe Martínez-Jaramillo, Patricia Flores-Guzmán, Enrique Miranda-Peralta, Mario Gutiérrez-Romero, Hector Mayani

    One has previously characterized two different hematopoietic cell populations (obtained by negative-selection) from normal bone marrow. Population I was enriched for CD34+ Lin- cells, whereas Population II was enriched for CD34+ CD38- Lin- cells. Both populations showed elevated proliferation and expansion potentials in serum-free liquid cultures, supplemented with a combination of eight different cytokines, with the latter displaying more immature features than the former. One has also characterized the chronic myeloid leukemia (CML) counterparts of these two populations and demonstrated functional deficiencies in terms of their growth in culture. In keeping with this line of research, the goal of the present study was to obtain the same two populations (Populations I and II) from acute myeloid leukemia (AML) bone marrow and to characterize their biological behavior under the same culture conditions. The results demonstrated that AML-derived Populations I and II were unable to proliferate in culture conditions that allowed significant proliferation of Populations I and II from normal marrow. Population I from AML also showed a deficient expansion capacity; in contrast, Population II cells were able to expand to a similar extent to the one observed for Population II from normal marrow. Both normal and AML populations were highly sensitive to the inhibitory effects of TNF-alpha; interestingly, whereas in normal fractions TNF-alpha showed a more pronounced inhibitory effect on more mature cells (Population I), this cytokine inhibited proliferation and expansion of AML Populations I and II in a similar degree. It is noteworthy that the functional deficiencies observed in AML cells were even more pronounced than those previously reported for cultures of CML cells. The results reported here may be of relevance considering the interest by several groups in developing methods for the in vitro purging of leukemic cells, as part of protocols for autologous transplantation of hematopoietic cells in leukemic patients.


  • NF-κB dependent activation of human endothelial cells treated with soluble products derived from human lymphomas

    by Adriana Estrada-Bernal, Criselda Mendoza-Milla, José Luis Ventura-Gallegos, Lucia Nikolaia López-Bojórquez, Enrique Miranda-Peralta, Fabián Arechavaleta-Velasco, Felipe Vadillo-Ortega, Luis Sánchez-Sánchez, Alejandro Zentella-Dehesa


  • Effect of rhGM-CSF on the Kinetics of Hematopoiesis in Long-term Marrow Cultures from Patients with Acute Myelogenous Leukemia

    by Juan José Montesinos, Elizabeth Sánchez-Valle, Enrique Miranda-Peralta, Mario Gutiérrez-Romero, Hector Mayani

    In the present study, we have assessed the effects of recombinant human Granulocyte-Macrophage Colony-Stimulating Factor (rhGM-CSF) in Dexter-type long-term marrow cultures (LTMC) from patients with acute myelogenous leukemia (AML). Addition of rhGM-CSF to AML LTMC resulted in a significant increase in the number of total nucleated cells (1.3-4.3-fold, as compared to untreated cultures). However, a simultaneous decrease in the numbers of myeloid progenitor cells (CFU) was observed. Interestingly, there was a selective stimulation of the growth of leukemic progenitors (AML-CFU). Indeed, whereas on day 0 these cells were detected in only 2 patients, between weeks 1 and 5 they were detected in 10 of the 14 patients included in the study. It is noteworthy that around 50% of the cells detected in the non-adherent fraction of rhGM-CSF-treated AML LTMC were blasts, whereas in untreated cultures, blasts corresponded to only 23% of the non-adherent cells, and the majority corresponded to cells of the monocyte-macrophage lineage. These results indicate that rhGM-CSF is a cytokine with a significant stimulatory activity for the in vitro growth of AML progenitor and blast cells, and, together with previous reports in the literature, suggest that the use of rhGM-CSF in clinical settings must be taken with caution since this cytokine, although beneficial in reducing the risk of infections after chemotherapy, may induce the reappearance of the disease after treatment. Further studies should be encouraged to understand in greater detail the effects of rhGM-CSF, and other cytokines, on the hematopoietic system of AML patients.